\-\ Texto\\:\\ \ \(0\)\
\-\ gen\\ \\-\\ cachectic\\ male\\,\\ lying\\ in\\ bed\\,\\ awake\\,\\ alert\\,\\ oriented\\ x3\ \(0\)\
\-\ heent\\ \\-\\ mmm\\,\\ perrl\\,\\ anicteric\\,\\ throat\\ non\\-erythematous\ \(0\)\
\-\ neck\\ \\-\\ supple\\,\\ no\\ palpable\\ lns\ \(0\)\
\-\ cv\\ \\-\\ rrr\\,\\ s1\\ s2\\ nml\\,\\ no\\ murmurs\ \(0\)\
\-\ resp\\ \\-\\ ctab\\,\\ no\\ crackles\\ or\\ wheezes\\,\\ r\\ hemidiaphragm\\ mildly\\ elevated\\ \ \(0\)\
\-\ abd\\ \\-\\ firm\\,\\ significantly\\ distended\\,\\ mildly\\ tender\\,\\ bs\\+\\ \ \(0\)\
\-\ ext\\ \\-\\ hands\\ and\\ feet\\ cold\\ to\\ touch\\,\\ 2\\+\\ edema\\ bilaterally\\,\\ pulses\\ 2\\+\\ bilaterally\\,\\ cap\\ refil\\ 2\\+\\ sec\ \(0\)\
\-\ neuro\\ \\-\\ cns\\ grossly\\ intact\\,\\ \\ strength\\/sensory\\ intact\\,\\ reflexes\\ 2\\+\\ bilaterally\ \(0\)\
\-\ s\\/p\\ surgical\\ resection\\ of\\ mass\\ without\\ symptoms\\ or\\ recurrence\\ to\\ date\\ \\(1\\ month\\)\\.\ \(0\)\
\-\ ct\\ abd\\/pelvis\ \(0\)\
\-\ 1\\.\\ there\\ is\\ a\\ massive\\ low\\ density\\ soft\\ tissue\\ mass\\ comprising\\ the\\ majority\\ of\\ the\\ anterior\\ and\\ mid\\ abdomen\\ as\\ well\\ as\\ the\\ pelvis\\.\\ the\\ mass\\ demonstrates\\ enhancing\\ septations\\.\\ it\\ is\\ predominantly\\ low\\ density\\.\\ some\\ of\\ the\\ areas\\ of\\ the\\ mass\\ more\\ centrally\\ are\\ lower\\ density\\ than\\ the\\ more\\ peripheral\\ portions\\ of\\ the\\ mass\\.\\ the\\ mass\\ almost\\ certainly\\ is\\ malignant\\.\\ tissue\\ sampling\\ is\\ recommended\\.\\ in\\ the\\ right\\ abdomen\\ there\\ is\\ small\\ low\\ density\\ area\\ which\\ may\\ represent\\ loculated\\ ascites\\ or\\ another\\ component\\ of\\ the\\ soft\\ tissue\\ mass\\ as\\ described\\ above\\.\ \(0\)\
\-\ 2\\.\\ there\\ is\\ a\\ small\\ amount\\ of\\ abdominal\\ and\\ pelvic\\ ascites\\ which\\ may\\ be\\ malignant\\ as\\ well\\.\\ \ \(0\)\
\-\ 3\\.\\ there\\ are\\ bilateral\\ pleural\\ effusions\\ and\\ dense\\ consolidation\\ in\\ the\\ lung\\ bases\\.\ \(0\)\
\-\ 4\\.\\ the\\ gallbladder\\ is\\ distended\\ and\\ there\\ is\\ a\\ small\\ amount\\ of\\ pericholecystic\\ fluid\\.\\ this\\ is\\ nonspecific\\.\ \(0\)\
\-\ pleomorphic\\ liposarcoma\ \(1\)\
\-\ malignant\\ neoplasm\ \(11\)\
\-\ 44\\ year\\-old\\ male\\ with\\ hx\\ of\\ h\\.\\ pylori\\ and\\ gastric\\ ulcers\\,\\ admitted\\ for\\ pre\\-op\\ treatment\\.\\ \\ patient\\ presented\\ to\\ outside\\ hospital\\ for\\ abdominal\\ mass\\ and\\ dysuria\\ 12\\/05\\,\\ imaging\\ followed\\ by\\ needle\\ biopsy\\ which\\ was\\ diagnosed\\ as\\ a\\ \\"gastrointestinal\\ stromal\\ tumor\\"\\.\\ \\ surgery\\ consult\\ at\\ that\\ time\\ suggested\\ neo\\-adjuvant\\ therapy\\ to\\ shrink\\ the\\ tumor\\ before\\ consideration\\ of\\ surgery\\.\\ \\ pt\\ took\\ gleevac\\ for\\ 2\\ months\\ with\\ no\\ effect\\ on\\ tumor\\ growth\\.\\ was\\ then\\ switched\\ to\\ sutant\\ for\\ 1\\ month\\,\\ which\\ he\\ stopped\\ a\\ few\\ days\\ prior\\ to\\ admission\\ because\\ of\\ nausea\\ and\\ vomiting\\.\\ \\ \\ pain\\ progressed\\ from\\ dysuria\\ to\\ diffuse\\ abdominal\\ pain\\ over\\ the\\ first\\ month\\,\\ but\\ is\\ currently\\ well\\ controlled\\ on\\ oral\\ morphine\\.\\ \\ appetite\\ is\\ present\\,\\ but\\ pt\\ is\\ unable\\ to\\ eat\\ normal\\ volumes\\ of\\ food\\ because\\ of\\ nausea\\ and\\ vomiting\\.\\ \\ according\\ to\\ family\\,\\ he\\ has\\ lost\\ 20\\+\\ lbs\\ since\\ the\\ onset\\ of\\ symptoms\\ 8\\ months\\ ago\\.\\ \\ \\ mild\\ pain\\ in\\ legs\\ and\\ sob\\ while\\ supine\\.\ \(0\)\
\-\ ros\\:\\ \\(\\+\\)\\ wt\\.\\ loss\\ of\\ 20\\+\\ lbs\\,\\ intermittent\\ sob\\ while\\ supine\\,\\ sometimes\\ sees\\ flashing\\ lights\\,\\ significant\\ weakness\\ and\\ fatigue\\,\\ mild\\ dysuria\\,\\ n\\/v\\,\\ reflux\\,\\ constipation\\ \\(d\\/t\\ narcotics\\)\\,\\ pain\\ in\\ legs\\ and\\ edema\\.\ \(0\)\
\-\ no\\ fevers\\,\\ chills\\,\\ cough\\,\\ hemoptysis\\.\\ \\ \ \(0\)\
\-\ no\\ chest\\ pain\\,\\ palpitations\\,\\ dyspnea\\ on\\ exertion\\.\\ \\ \ \(0\)\
\-\ no\\ diarrhea\\,\\ melena\\/brbpr\\.\\ \ \(0\)\
\-\ no\\ hematuria\\.\\ \\ \ \(0\)\
\-\ no\\ headache\\,\\ numbness\\,\\ lightheadedness\ \(0\)\
\-\ pmh\\:\\ gastric\\ ulcers\\,\\ h\\.\\ pylori\\ 2002\ \(0\)\
\-\ psh\\:\\ none\ \(0\)\
\-\ liposarcoma\\ is\\ a\\ malignancy\\ of\\ fat\\ cells\\.\\ in\\ adults\\,\\ it\\ is\\ the\\ most\\ common\\ soft\\ tissue\\ sarcoma\\.\\ liposarcoma\\ normally\\ appears\\ as\\ a\\ slowly\\ enlarging\\,\\ painless\\,\\ nonulcerated\\ submucosal\\ mass\\ in\\ a\\ middle\\-aged\\ person\\,\\ but\\ some\\ lesions\\ grow\\ rapidly\\ and\\ become\\ ulcerated\\ early\\.\\ virchow\\ first\\ described\\ liposarcoma\\ in\\ the\\ 1860s\\.\\ \ \(0\)\
\-\ the\\ development\\ of\\ a\\ liposarcoma\\ from\\ a\\ preexisting\\ benign\\ lipoma\\ is\\ rare\\.\\ most\\ cases\\ arise\\ de\\ novo\\.\\ liposarcomas\\ most\\ frequently\\ arise\\ from\\ the\\ deep\\-seated\\ stroma\\ rather\\ than\\ the\\ submucosal\\ or\\ subcutaneous\\ fat\\.\\ the\\ most\\ recent\\ world\\ health\\ organization\\ classification\\ of\\ soft\\ tissue\\ tumors\\ recognizes\\ 5\\ categories\\ of\\ liposarcomas\\:\\ \\(1\\)\\ well\\ differentiated\\,\\ which\\ includes\\ the\\ adipocytic\\,\\ sclerosing\\,\\ and\\ inflammatory\\ subtypes\\;\\ \\(2\\)\\ dedifferentiated\\;\\ \\(3\\)\\ myxoid\\;\\ \\(4\\)\\ round\\ cell\\;\\ and\\ \\(5\\)\\ pleomorphic\\.\\ \ \(0\)\
\-\ the\\ anatomical\\ distribution\\ of\\ liposarcoma\\ appears\\ to\\ be\\ partly\\ related\\ to\\ the\\ histologic\\ type\\.\\ well\\-differentiated\\ liposarcoma\\ tends\\ to\\ occur\\ in\\ deep\\ soft\\ tissues\\ of\\ both\\ the\\ limbs\\ and\\ the\\ retroperitoneum\\.\\ myxoid\\ and\\/or\\ round\\-cell\\ liposarcomas\\ and\\ pleomorphic\\ liposarcomas\\ have\\ a\\ striking\\ predilection\\ for\\ the\\ limbs\\,\\ and\\ dedifferentiated\\ liposarcoma\\ occurs\\ predominantly\\ in\\ the\\ retroperitoneum\\.\\ although\\ any\\ liposarcoma\\ subtype\\ occasionally\\ arises\\ in\\ the\\ subcutis\\,\\ involvement\\ of\\ the\\ dermis\\ appears\\ to\\ be\\ exceedingly\\ rare\\.\ \(0\)\
\-\ the\\ overall\\ 5\\-year\\ survival\\ rate\\ of\\ patients\\ with\\ deep\\ high\\-grade\\ liposarcoma\\ is\\ less\\ than\\ 50\\%\\.\\ \ \(0\)\
\-\ metastases\\ are\\ common\\,\\ especially\\ in\\ poorly\\ differentiated\\ liposarcomas\\.\\ the\\ lungs\\ and\\ the\\ liver\\ are\\ the\\ most\\ common\\ sites\\ of\\ metastasis\\.\\ \ \(0\)\
\-\ primary\\ cutaneous\\ liposarcoma\\ has\\ an\\ indolent\\ course\\.\\ \ \(0\)\
\-\ no\\ association\\ with\\ race\\ or\\ geography\\ is\\ known\\.\\ liposarcomas\\ are\\ slightly\\ more\\ common\\ in\\ males\\ than\\ in\\ females\\.\\ \ \(0\)\
\-\ the\\ mean\\ patient\\ age\\ at\\ onset\\ is\\ 50\\ years\\.\\ \ \(0\)\
\-\ although\\ liposarcomas\\ account\\ for\\ about\\ 17\\%\\ of\\ all\\ soft\\ tissue\\ sarcomas\\,\\ they\\ are\\ involved\\ in\\ only\\ 4\\%\\ of\\ childhood\\ soft\\ tissue\\ sarcomas\\.\\ cases\\ of\\ liposarcoma\\ are\\ reported\\ in\\ young\\ adults\\ and\\ teenagers\\,\\ but\\ cases\\ in\\ children\\ are\\ rare\\.\\ \ \(0\)\
\-\ in\\ the\\ case\\ of\\ well\\-differentiated\\ liposarcoma\\,\\ grade\\ provides\\ no\\ incremental\\ information\\ over\\ other\\ histological\\ subtypes\\ in\\ terms\\ of\\ response\\ to\\ therapy\\.\\ in\\ myxoid\\/round\\ cell\\ liposarcoma\\,\\ the\\ presence\\ of\\ a\\ round\\ cell\\ component\\ may\\ be\\ an\\ adverse\\ prognostic\\ sign\\.\\ tumor\\ site\\,\\ a\\ high\\ proliferative\\ fraction\\ noted\\ with\\ mib\\-1\\ labeling\\,\\ and\\ tp53\\ missense\\ mutations\\ are\\ also\\ adverse\\ prognostic\\ factors\\ in\\ myxoid\\/round\\ cell\\ tumors\\.\ \(0\)\
\-\ the\\ prognosis\\ is\\ affected\\ by\\ the\\ type\\ of\\ liposarcoma\\ present\\.\ \(0\)\
\-\ the\\ well\\-differentiated\\ type\\ and\\ most\\ myxoid\\ types\\ have\\ favorable\\ prognoses\\,\\ with\\ 100\\%\\ and\\ 88\\%\\ 5\\-year\\ survival\\ rates\\,\\ respectively\\.\\ however\\,\\ these\\ tumors\\ are\\ poorly\\ circumscribed\\ and\\ locally\\ recur\\ after\\ incomplete\\ excision\\.\\ although\\ they\\ rarely\\ metastasize\\,\\ repeated\\ local\\ recurrences\\ may\\ cause\\ the\\ tumor\\ to\\ evolve\\ into\\ a\\ higher\\ grade\\ of\\ sarcoma\\ or\\ to\\ dedifferentiate\\,\\ in\\ which\\ case\\ metastasis\\ is\\ possible\\.\ \(0\)\
\-\ the\\ form\\ that\\ a\\ dermatologist\\ is\\ most\\ likely\\ to\\ examine\\ at\\ biopsy\\ is\\ 1\\ of\\ the\\ 3\\ subtypes\\ of\\ a\\ well\\-differentiated\\ liposarcoma\\,\\ that\\ is\\,\\ the\\ lipomalike\\ liposarcoma\\ or\\ atypical\\ lipoma\\;\\ the\\ other\\ 2\\,\\ inflammatory\\ and\\ sclerosing\\,\\ are\\ less\\ likely\\.\\ the\\ clinical\\ outcome\\ of\\ this\\ subtype\\ is\\ best\\ predicted\\ by\\ the\\ anatomical\\ location\\.\\ in\\ the\\ subcutis\\,\\ lipomalike\\ liposarcomas\\ are\\ often\\ cured\\ with\\ local\\ excision\\.\\ lipomalike\\ liposarcomas\\ rarely\\ recur\\,\\ and\\ they\\ do\\ not\\ metastasize\\.\\ use\\ of\\ the\\ term\\ atypical\\ lipomatous\\ tumor\\,\\ a\\ less\\ serious\\ designation\\ for\\ atypical\\ lipoma\\,\\ has\\ been\\ suggested\\.\ \(0\)\
\-\ round\\-cell\\ and\\ poorly\\ differentiated\\ types\\ have\\ a\\ poor\\ prognosis\\.\\ each\\ has\\ a\\ 5\\-year\\ survival\\ rate\\ of\\ about\\ 50\\%\\ because\\ they\\ recur\\ locally\\ and\\ tend\\ to\\ metastasize\\ quickly\\ and\\ widely\\.\\ the\\ lungs\\ are\\ particularly\\ affected\\.\ \(0\)\
\-\ despite\\ high\\-grade\\ morphology\\,\\ cutaneous\\ liposarcomas\\ have\\ a\\ favorable\\ clinical\\ prognosis\\.\ \(0\)\
\-\ \\ \\ \ \(31891\)\
\-\ references\\:\ \(0\)\
\-\ 1\\.\\ allen\\ pw\\,\\ strungs\\ i\\,\\ maccormac\\ lb\\.\\ atypical\\ subcutaneous\\ fatty\\ tumors\\:\\ a\\ review\\ of\\ 37\\ referred\\ cases\\.\\ pathology\\ 1998\\;30\\(2\\)\\:\\ 123\\-35\\.\\ \ \(0\)\
\-\ 2\\.\\ antonescu\\ cr\\.\\ the\\ role\\ of\\ genetic\\ testing\\ in\\ soft\\ tissue\\ sarcoma\\.\\ histopathology\\ 2006\\;48\\(1\\)\\:13\\-21\\.\\ \ \(0\)\
\-\ azumi\\ n\\,\\ curtis\\ j\\,\\ kempson\\ rl\\,\\ hendrickson\\ mr\\.\\ atypical\\ and\\ malignant\\ neoplasms\\ showing\\ lipomatous\\ differentiation\\.\\ a\\ study\\ of\\ 111\\ cases\\.\\ am\\ j\\ surg\\ pathol\\ 1987\\;11\\(3\\)\\:161\\-83\\.\\ \ \(0\)\
\-\ 3\\.\\ binh\\ mb\\,\\ sastre\\-garau\\ x\\,\\ guillou\\ l\\,\\ et\\ al\\.\\ mdm2\\ and\\ cdk4\\ immunostainings\\ are\\ useful\\ adjuncts\\ in\\ diagnosing\\ well\\-differentiatedand\\ dedifferentiated\\ liposarcoma\\ subtypes\\:\\ a\\ comparative\\ analysis\\ of\\ 559\\ soft\\ tissue\\ neoplasms\\ with\\ geneticdata\\.\\ am\\ j\\ surg\\ pathol\\ 2005\\;29\\(10\\)\\:1340\\-7\\.\\ \ \(0\)\
\-\ 4\\.\\ dei\\ tos\\ ap\\,\\ mentzel\\ t\\,\\ fletcher\\ cd\\:\\ primary\\ liposarcoma\\ of\\ the\\ skin\\:\\ a\\ rare\\ neoplasm\\ with\\ unusual\\ high\\ grade\\ features\\.\\ am\\ j\\ dermatopathol\\ 1998\\;20\\(4\\)\\:332\\-8\\.\\ \ \(0\)\
\-\ 5\\.\\ deyrup\\ at\\,\\ weiss\\ sw\\:\\ grading\\ of\\ soft\\ tissue\\ sarcomas\\:\\ the\\ challenge\\ of\\ providing\\ precise\\ informationin\\ an\\ imprecise\\ world\\.\\ histopathology\\ 2006\\;48\\(1\\)\\:42\\-50\\.\\ \ \(0\)\
\-\ 6\\.\\ enzinger\\ fm\\,\\ weiss\\ sw\\.\\ liposarcoma\\.\\ in\\:\\ enzinger\\ and\\ weiss\\'s\\ soft\\ tissue\\ tumors\\.\\ 3rd\\ ed\\.\\ mosby\\-year\\ book\\;\\ 1995\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ liposarcoma\\:\\ 0\\.07297389203734918\ \(0\)\
\-\ liposarcomas\\:\\ 0\\.06243285002809135\ \(0\)\
\-\ lipomalike\\:\\ 0\\.018729855008427405\ \(0\)\
\-\ well\\-differentiated\\:\\ 0\\.01845023606507777\ \(0\)\
\-\ \\;\\:\\ 0\\.017213211233308164\ \(0\)\
\-\ subtypes\\:\\ 0\\.01634843055592939\ \(0\)\
\-\ \\,\\:\\ 0\\.016296285813717726\ \(0\)\
\-\ soft\\:\\ 0\\.016211185838476663\ \(0\)\
\-\ dedifferentiated\\:\\ 0\\.015784470388484295\ \(0\)\
\-\ weiss\\:\\ 0\\.015784470388484295\ \(0\)\
\-\ tissue\\:\\ 0\\.015778776963865815\ \(0\)\
\-\ myxoid\\:\\ 0\\.013280245892007709\ \(0\)\
\-\ 5\\-year\\:\\ 0\\.013280245892007709\ \(0\)\
\-\ sarcomas\\:\\ 0\\.013280245892007709\ \(0\)\
\-\ atypical\\:\\ 0\\.013114485253576329\ \(0\)\
\-\ metastasize\\:\\ 0\\.012839085768541184\ \(0\)\
\-\ round\\-cell\\:\\ 0\\.01248657000561827\ \(0\)\
\-\ enzinger\\:\\ 0\\.01248657000561827\ \(0\)\
\-\ 2\\+\\:\\ 0\\.012387725686901364\ \(0\)\
\-\ recur\\:\\ 0\\.012261322916947044\ \(0\)\
\-\ dysuria\\:\\ 0\\.011807553582036154\ \(0\)\
\-\ are\\:\\ 0\\.011549740945760924\ \(0\)\
\-\ myxoid\\/round\\:\\ 0\\.0115047751323039\ \(0\)\
\-\ sw\\:\\ 0\\.0115047751323039\ \(0\)\
\-\ tumors\\:\\ 0\\.011365851124895542\ \(0\)\
\-\ j\\:\\ 0\\.010933969876388776\ \(0\)\
\-\ subcutis\\:\\ 0\\.010930461948014714\ \(0\)\
\-\ 20\\+\\:\\ 0\\.010522980258989529\ \(0\)\
\-\ \\:\\:\\ 0\\.01040621289509819\ \(0\)\
\-\ \\-\\:\\ 0\\.010378064921860417\ \(0\)\
\-\ pleomorphic\\:\\ 0\\.010215691017140285\ \(0\)\
\-\ cases\\:\\ 0\\.010080775014097494\ \(0\)\
\-\ most\\:\\ 0\\.009780344187037203\ \(0\)\
\-\ survival\\:\\ 0\\.009733878015657024\ \(0\)\
\-\ differentiated\\:\\ 0\\.0097033070437333\ \(0\)\
\-\ is\\:\\ 0\\.009557350340816867\ \(0\)\
\-\ rare\\:\\ 0\\.009400425491992341\ \(0\)\
\-\ lipomatous\\:\\ 0\\.00937435389041116\ \(0\)\
\-\ pathol\\:\\ 0\\.00937435389041116\ \(0\)\
\-\ am\\:\\ 0\\.009341383462117353\ \(0\)\
\-\ world\\:\\ 0\\.009225118032538886\ \(0\)\
\-\ poorly\\:\\ 0\\.008862168962093044\ \(0\)\
\-\ pylori\\:\\ 0\\.008853497261338472\ \(0\)\
\-\ retroperitoneum\\:\\ 0\\.008853497261338472\ \(0\)\
\-\ malignant\\:\\ 0\\.008749775287193487\ \(0\)\
\-\ adverse\\:\\ 0\\.008748528462253881\ \(0\)\
\-\ they\\:\\ 0\\.008722226987216164\ \(0\)\
\-\ 1\\:\\ 0\\.008640197030990256\ \(0\)\
\-\ prognosis\\:\\ 0\\.008611921719197045\ \(0\)\
\-\ lipoma\\:\\ 0\\.008488463580088092\ \(0\)\
\-\ \\%\\:\\ 0\\.008470202691271987\ \(0\)\
\-\ tumor\\:\\ 0\\.008465576352453872\ \(0\)\
\-\ locally\\:\\ 0\\.008315976550708298\ \(0\)\
\-\ high\\-grade\\:\\ 0\\.008243323159224514\ \(0\)\
\-\ limbs\\:\\ 0\\.008174215277964695\ \(0\)\
\-\ subtype\\:\\ 0\\.008174215277964695\ \(0\)\
\-\ prognostic\\:\\ 0\\.008108322904544168\ \(0\)\
\-\ sarcoma\\:\\ 0\\.008084029312755474\ \(0\)\
\-\ density\\:\\ 0\\.007964961350878071\ \(0\)\
\-\ favorable\\:\\ 0\\.007871702388024102\ \(0\)\
\-\ h\\.\\:\\ 0\\.0077667335889395105\ \(0\)\
\-\ in\\:\\ 0\\.007759439081902711\ \(0\)\
\-\ 1998\\:\\ 0\\.0077170291699433765\ \(0\)\
\-\ submucosal\\:\\ 0\\.00766900997493533\ \(0\)\
\-\ anatomical\\:\\ 0\\.007622565466687468\ \(0\)\
\-\ mass\\:\\ 0\\.007575176389892408\ \(0\)\
\-\ surg\\:\\ 0\\.0072265529139691085\ \(0\)\
\-\ \\(\\:\\ 0\\.007162226747460373\ \(0\)\
\-\ sclerosing\\:\\ 0\\.007159091088205291\ \(0\)\
\-\ ulcers\\:\\ 0\\.007126528031229797\ \(0\)\
\-\ \\)\\:\\ 0\\.007074736324069597\ \(0\)\
\-\ sob\\:\\ 0\\.0070635651947272005\ \(0\)\
\-\ cutaneous\\:\\ 0\\.0070331031476720115\ \(0\)\
\-\ lbs\\:\\ 0\\.006974076665518232\ \(0\)\
\-\ 2006\\:\\ 0\\.006974076665518232\ \(0\)\
\-\ ascites\\:\\ 0\\.00694546093277387\ \(0\)\
\-\ grade\\:\\ 0\\.006915375622417077\ \(0\)\
\-\ 50\\:\\ 0\\.006907219582104401\ \(0\)\
\-\ which\\:\\ 0\\.006778234789982502\ \(0\)\
\-\ supine\\:\\ 0\\.006759868493104742\ \(0\)\
\-\ histopathology\\:\\ 0\\.006759868493104742\ \(0\)\
\-\ appears\\:\\ 0\\.006757922423790189\ \(0\)\
\-\ a\\:\\ 0\\.0067410731187297675\ \(0\)\
\-\ no\\:\\ 0\\.006703176811431885\ \(0\)\
\-\ legs\\:\\ 0\\.006552214846940613\ \(0\)\
\-\ cell\\:\\ 0\\.0065389255285594515\ \(0\)\
\-\ because\\:\\ 0\\.0063516678114434455\ \(0\)\
\-\ than\\:\\ 0\\.006342914603167915\ \(0\)\
\-\ common\\:\\ 0\\.00633503459477733\ \(0\)\
\-\ subcutaneous\\:\\ 0\\.006297550384560166\ \(0\)\
\-\ lns\\:\\ 0\\.006243285002809135\ \(0\)\
\-\ refil\\:\\ 0\\.006243285002809135\ \(0\)\
\-\ strength\\/sensory\\:\\ 0\\.006243285002809135\ \(0\)\
\-\ 12\\/05\\:\\ 0\\.006243285002809135\ \(0\)\
\-\ neo\\-adjuvant\\:\\ 0\\.006243285002809135\ \(0\)\
\-\ sutant\\:\\ 0\\.006243285002809135\ \(0\)\
\-\ sees\\:\\ 0\\.006243285002809135\ \(0\)\
\-\ flashing\\:\\ 0\\.006243285002809135\ \(0\)\
\-\ melena\\/brbpr\\:\\ 0\\.006243285002809135\ \(0\)\
\-\ nonulcerated\\:\\ 0\\.006243285002809135\ \(0\)\
\-\ 1860s\\:\\ 0\\.006243285002809135\ \(0\)\
\-\ deep\\-seated\\:\\ 0\\.006243285002809135\ \(0\)\
\-\ recognizes\\:\\ 0\\.006243285002809135\ \(0\)\
\-\ adipocytic\\:\\ 0\\.006243285002809135\ \(0\)\
\-\ geography\\:\\ 0\\.006243285002809135\ \(0\)\
\-\ incremental\\:\\ 0\\.006243285002809135\ \(0\)\
\-\ tp53\\:\\ 0\\.006243285002809135\ \(0\)\
\-\ missense\\:\\ 0\\.006243285002809135\ \(0\)\
\-\ dedifferentiate\\:\\ 0\\.006243285002809135\ \(0\)\
\-\ pw\\:\\ 0\\.006243285002809135\ \(0\)\
\-\ strungs\\:\\ 0\\.006243285002809135\ \(0\)\
\-\ maccormac\\:\\ 0\\.006243285002809135\ \(0\)\
\-\ 123\\-35\\:\\ 0\\.006243285002809135\ \(0\)\
\-\ antonescu\\:\\ 0\\.006243285002809135\ \(0\)\
\-\ \\:13\\-21\\.\\:\\ 0\\.006243285002809135\ \(0\)\
\-\ azumi\\:\\ 0\\.006243285002809135\ \(0\)\
\-\ kempson\\:\\ 0\\.006243285002809135\ \(0\)\
\-\ hendrickson\\:\\ 0\\.006243285002809135\ \(0\)\
\-\ \\:161\\-83\\:\\ 0\\.006243285002809135\ \(0\)\
\-\ binh\\:\\ 0\\.006243285002809135\ \(0\)\
\-\ sastre\\-garau\\:\\ 0\\.006243285002809135\ \(0\)\
\-\ guillou\\:\\ 0\\.006243285002809135\ \(0\)\
\-\ mdm2\\:\\ 0\\.006243285002809135\ \(0\)\
\-\ cdk4\\:\\ 0\\.006243285002809135\ \(0\)\
\-\ immunostainings\\:\\ 0\\.006243285002809135\ \(0\)\
\-\ well\\-differentiatedand\\:\\ 0\\.006243285002809135\ \(0\)\
\-\ 559\\:\\ 0\\.006243285002809135\ \(0\)\
\-\ geneticdata\\:\\ 0\\.006243285002809135\ \(0\)\
\-\ \\:1340\\-7\\:\\ 0\\.006243285002809135\ \(0\)\
\-\ dei\\:\\ 0\\.006243285002809135\ \(0\)\
\-\ mentzel\\:\\ 0\\.006243285002809135\ \(0\)\
\-\ fletcher\\:\\ 0\\.006243285002809135\ \(0\)\
\-\ dermatopathol\\:\\ 0\\.006243285002809135\ \(0\)\
\-\ \\:332\\-8\\:\\ 0\\.006243285002809135\ \(0\)\
\-\ deyrup\\:\\ 0\\.006243285002809135\ \(0\)\
\-\ informationin\\:\\ 0\\.006243285002809135\ \(0\)\
\-\ imprecise\\:\\ 0\\.006243285002809135\ \(0\)\
\-\ \\:42\\-50\\:\\ 0\\.006243285002809135\ \(0\)\
\-\ adults\\:\\ 0\\.006177296214890921\ \(0\)\
\-\ types\\:\\ 0\\.006177296214890921\ \(0\)\
\-\ suggested\\:\\ 0\\.006160921112339823\ \(0\)\
\-\ neoplasms\\:\\ 0\\.006160921112339823\ \(0\)\
\-\ less\\:\\ 0\\.006148597742895218\ \(0\)\
\-\ although\\:\\ 0\\.006131577791593351\ \(0\)\
\-\ type\\:\\ 0\\.006120306434164825\ \(0\)\
\-\ arise\\:\\ 0\\.005992281792203862\ \(0\)\
\-\ bilaterally\\:\\ 0\\.005963254756070617\ \(0\)\
\-\ 48\\:\\ 0\\.005921798067615953\ \(0\)\
\-\ distended\\:\\ 0\\.005854656086178865\ \(0\)\
\-\ rarely\\:\\ 0\\.00580314384231077\ \(0\)\
\-\ gleevac\\:\\ 0\\.00575238756615195\ \(0\)\
\-\ lights\\:\\ 0\\.00575238756615195\ \(0\)\
\-\ mib\\-1\\:\\ 0\\.00575238756615195\ \(0\)\
\-\ prognoses\\:\\ 0\\.00575238756615195\ \(0\)\
\-\ curtis\\:\\ 0\\.00575238756615195\ \(0\)\
\-\ mosby\\-year\\:\\ 0\\.00575238756615195\ \(0\)\
\-\ predominantly\\:\\ 0\\.005670444856365553\ \(0\)\
\-\ local\\:\\ 0\\.005559729880658278\ \(0\)\
\-\ component\\:\\ 0\\.0055281353232725875\ \(0\)\
\-\ as\\:\\ 0\\.005492538976887229\ \(0\)\
\-\ well\\:\\ 0\\.005476150008409776\ \(0\)\
\-\ preexisting\\:\\ 0\\.005465230974007357\ \(0\)\
\-\ adjuncts\\:\\ 0\\.005465230974007357\ \(0\)\
\-\ tos\\:\\ 0\\.005465230974007357\ \(0\)\
\-\ month\\:\\ 0\\.005446773103684015\ \(0\)\
\-\ to\\:\\ 0\\.005444211014145717\ \(0\)\
\-\ gastric\\:\\ 0\\.005408365651844735\ \(0\)\
\-\ may\\:\\ 0\\.0053097120931958185\ \(0\)\
\-\ the\\:\\ 0\\.005287153947589089\ \(0\)\
\-\ bs\\+\\:\\ 0\\.0052614901294947645\ \(0\)\
\-\ d\\/t\\:\\ 0\\.0052614901294947645\ \(0\)\
\-\ lightheadedness\\:\\ 0\\.0052614901294947645\ \(0\)\
\-\ organization\\:\\ 0\\.0052614901294947645\ \(0\)\
\-\ teenagers\\:\\ 0\\.0052614901294947645\ \(0\)\
\-\ examine\\:\\ 0\\.0052614901294947645\ \(0\)\
\-\ designation\\:\\ 0\\.0052614901294947645\ \(0\)\
\-\ mb\\:\\ 0\\.0052614901294947645\ \(0\)\
\-\ fm\\:\\ 0\\.0052614901294947645\ \(0\)\
\-\ have\\:\\ 0\\.005242034216331705\ \(0\)\
\-\ affected\\:\\ 0\\.005237286985197937\ \(0\)\
\-\ round\\:\\ 0\\.005228830658021585\ \(0\)\
\-\ 2\\:\\ 0\\.0052127606133443236\ \(0\)\
\-\ but\\:\\ 0\\.005162898869783393\ \(0\)\
\-\ mildly\\:\\ 0\\.005154913160612846\ \(0\)\
\-\ described\\:\\ 0\\.005154913160612846\ \(0\)\
\-\ novo\\:\\ 0\\.005103456452926628\ \(0\)\
\-\ partly\\:\\ 0\\.005103456452926628\ \(0\)\
\-\ indolent\\:\\ 0\\.005103456452926628\ \(0\)\
\-\ dermatologist\\:\\ 0\\.005103456452926628\ \(0\)\
\-\ allen\\:\\ 0\\.005103456452926628\ \(0\)\
\-\ rl\\:\\ 0\\.005103456452926628\ \(0\)\
\-\ 4\\:\\ 0\\.005058722178142448\ \(0\)\
\-\ amount\\:\\ 0\\.005054524577628913\ \(0\)\
\-\ low\\:\\ 0\\.005048515693058923\ \(0\)\
\-\ cachectic\\:\\ 0\\.004974333537350172\ \(0\)\
\-\ exceedingly\\:\\ 0\\.004974333537350172\ \(0\)\
\-\ predicted\\:\\ 0\\.004974333537350172\ \(0\)\
\-\ book\\:\\ 0\\.004974333537350172\ \(0\)\
\-\ excision\\:\\ 0\\.004967777233095316\ \(0\)\
\-\ or\\:\\ 0\\.004965056120924896\ \(0\)\
\-\ deep\\:\\ 0\\.004899337321946863\ \(0\)\
\-\ nausea\\:\\ 0\\.004872861212864494\ \(0\)\
\-\ non\\-erythematous\\:\\ 0\\.0048651616677841255\ \(0\)\
\-\ abd\\/pelvis\\:\\ 0\\.0048651616677841255\ \(0\)\
\-\ shrink\\:\\ 0\\.0048651616677841255\ \(0\)\
\-\ eat\\:\\ 0\\.0048651616677841255\ \(0\)\
\-\ virchow\\:\\ 0\\.0048651616677841255\ \(0\)\
\-\ narcotics\\:\\ 0\\.0047705926928375796\ \(0\)\
\-\ labeling\\:\\ 0\\.0047705926928375796\ \(0\)\
\-\ mutations\\:\\ 0\\.0047705926928375796\ \(0\)\
\-\ evolve\\:\\ 0\\.0047705926928375796\ \(0\)\
\-\ comparative\\:\\ 0\\.0047705926928375796\ \(0\)\
\-\ 4\\.\\:\\ 0\\.004765552366006796\ \(0\)\
\-\ rate\\:\\ 0\\.004717735822203744\ \(0\)\
\-\ n\\/v\\:\\ 0\\.00468717694520558\ \(0\)\
\-\ cured\\:\\ 0\\.00468717694520558\ \(0\)\
\-\ 1987\\:\\ 0\\.00468717694520558\ \(0\)\
\-\ cd\\:\\ 0\\.00468717694520558\ \(0\)\
\-\ challenge\\:\\ 0\\.00468717694520558\ \(0\)\
\-\ about\\:\\ 0\\.004665803833008856\ \(0\)\
\-\ vomiting\\:\\ 0\\.004621188157287366\ \(0\)\
\-\ mmm\\:\\ 0\\.004612559016269443\ \(0\)\
\-\ comprising\\:\\ 0\\.004612559016269443\ \(0\)\
\-\ switched\\:\\ 0\\.004612559016269443\ \(0\)\
\-\ middle\\-aged\\:\\ 0\\.004612559016269443\ \(0\)\
\-\ race\\:\\ 0\\.004612559016269443\ \(0\)\
\-\ lungs\\:\\ 0\\.004583269968810589\ \(0\)\
\-\ has\\:\\ 0\\.004545892267689173\ \(0\)\
\-\ proliferative\\:\\ 0\\.004545058888929269\ \(0\)\
\-\ recurrences\\:\\ 0\\.004545058888929269\ \(0\)\
\-\ grading\\:\\ 0\\.004545058888929269\ \(0\)\
\-\ more\\:\\ 0\\.004540742866810552\ \(0\)\
\-\ abdominal\\:\\ 0\\.004538072035670217\ \(0\)\
\-\ metastasis\\:\\ 0\\.004530803578328508\ \(0\)\
\-\ there\\:\\ 0\\.004503242055470923\ \(0\)\
\-\ pt\\:\\ 0\\.004500231947071887\ \(0\)\
\-\ anicteric\\:\\ 0\\.004483436100692987\ \(0\)\
\-\ sampling\\:\\ 0\\.004483436100692987\ \(0\)\
\-\ morphine\\:\\ 0\\.004483436100692987\ \(0\)\
\-\ ulcerated\\:\\ 0\\.004483436100692987\ \(0\)\
\-\ 111\\:\\ 0\\.004483436100692987\ \(0\)\
\-\ precise\\:\\ 0\\.004483436100692987\ \(0\)\
\-\ intact\\:\\ 0\\.004445842240365746\ \(0\)\
\-\ x3\\:\\ 0\\.004374264231126941\ \(0\)\
\-\ sec\\:\\ 0\\.004374264231126941\ \(0\)\
\-\ biopsy\\:\\ 0\\.004294183061808443\ \(0\)\
\-\ perrl\\:\\ 0\\.004279695256180395\ \(0\)\
\-\ psh\\:\\ 0\\.004279695256180395\ \(0\)\
\-\ providing\\:\\ 0\\.004279695256180395\ \(0\)\
\-\ 3\\:\\ 0\\.004251364433512478\ \(0\)\
\-\ certainly\\:\\ 0\\.0042367599716078485\ \(0\)\
\-\ lb\\:\\ 0\\.0042367599716078485\ \(0\)\
\-\ inflammatory\\:\\ 0\\.004197331365711082\ \(0\)\
\-\ small\\:\\ 0\\.004182525391744587\ \(0\)\
\-\ nml\\:\\ 0\\.004157988275354149\ \(0\)\
\-\ 3\\.\\:\\ 0\\.004141464889717744\ \(0\)\
\-\ neoplasm\\:\\ 0\\.004122034810073553\ \(0\)\
\-\ categories\\:\\ 0\\.004121661579612257\ \(0\)\
\-\ striking\\:\\ 0\\.004121661579612257\ \(0\)\
\-\ fraction\\:\\ 0\\.004121661579612257\ \(0\)\
\-\ resp\\:\\ 0\\.0040871076389823475\ \(0\)\
\-\ stroma\\:\\ 0\\.0040871076389823475\ \(0\)\
\-\ quickly\\:\\ 0\\.0040871076389823475\ \(0\)\
\-\ and\\:\\ 0\\.004079524209228747\ \(0\)\
\-\ first\\:\\ 0\\.004061591267402057\ \(0\)\
\-\ volumes\\:\\ 0\\.004054161452272084\ \(0\)\
\-\ ros\\:\\ 0\\.004054161452272084\ \(0\)\
\-\ palpitations\\:\\ 0\\.004054161452272084\ \(0\)\
\-\ de\\:\\ 0\\.004022680034020785\ \(0\)\
\-\ awake\\:\\ 0\\.003992538664035802\ \(0\)\
\-\ tends\\:\\ 0\\.003992538664035802\ \(0\)\
\-\ predilection\\:\\ 0\\.003992538664035802\ \(0\)\
\-\ widely\\:\\ 0\\.003992538664035802\ \(0\)\
\-\ loculated\\:\\ 0\\.00396362790304412\ \(0\)\
\-\ pre\\-op\\:\\ 0\\.00396362790304412\ \(0\)\
\-\ took\\:\\ 0\\.00396362790304412\ \(0\)\
\-\ 88\\:\\ 0\\.00396362790304412\ \(0\)\
\-\ grow\\:\\ 0\\.003935851194012051\ \(0\)\
\-\ person\\:\\ 0\\.003909122916403803\ \(0\)\
\-\ terms\\:\\ 0\\.003909122916403803\ \(0\)\
\-\ wt\\:\\ 0\\.0038833667944697552\ \(0\)\
\-\ dermis\\:\\ 0\\.0038833667944697552\ \(0\)\
\-\ serious\\:\\ 0\\.0038833667944697552\ \(0\)\
\-\ cap\\:\\ 0\\.0038585145849716882\ \(0\)\
\-\ diagnosing\\:\\ 0\\.0038585145849716882\ \(0\)\
\-\ 2\\.\\:\\ 0\\.0038490710223799693\ \(0\)\
\-\ pericholecystic\\:\\ 0\\.003834504987467665\ \(0\)\
\-\ stopped\\:\\ 0\\.003834504987467665\ \(0\)\
\-\ histologic\\:\\ 0\\.003834504987467665\ \(0\)\
\-\ onset\\:\\ 0\\.00382070995173534\ \(0\)\
\-\ while\\:\\ 0\\.00380828504228373\ \(0\)\
\-\ 1\\.\\:\\ 0\\.0037807211987218145\ \(0\)\
\-\ stromal\\:\\ 0\\.0037670048601274914\ \(0\)\
\-\ mean\\:\\ 0\\.0037670048601274914\ \(0\)\
\-\ histological\\:\\ 0\\.0037670048601274914\ \(0\)\
\-\ supple\\:\\ 0\\.0037458625349506636\ \(0\)\
\-\ ctab\\:\\ 0\\.0037458625349506636\ \(0\)\
\-\ provides\\:\\ 0\\.0037458625349506636\ \(0\)\
\-\ 1995\\:\\ 0\\.0037458625349506636\ \(0\)\
\-\ be\\:\\ 0\\.0037330218791612724\ \(0\)\
\-\ constipation\\:\\ 0\\.003725333117901618\ \(0\)\
\-\ clinical\\:\\ 0\\.0037242348442861253\ \(0\)\
\-\ ext\\:\\ 0\\.00370538207189121\ \(0\)\
\-\ septations\\:\\ 0\\.00370538207189121\ \(0\)\
\-\ pain\\:\\ 0\\.003695496343947361\ \(0\)\
\-\ fat\\:\\ 0\\.0036811789275943817\ \(0\)\
\-\ some\\:\\ 0\\.0036755357703495174\ \(0\)\
\-\ wheezes\\:\\ 0\\.003648694601867459\ \(0\)\
\-\ cold\\:\\ 0\\.003648694601867459\ \(0\)\
\-\ controlled\\:\\ 0\\.003630764142955072\ \(0\)\
\-\ arises\\:\\ 0\\.003630764142955072\ \(0\)\
\-\ cr\\:\\ 0\\.003630764142955072\ \(0\)\
\-\ of\\:\\ 0\\.0036304300531951068\ \(0\)\
\-\ for\\:\\ 0\\.003614558810551704\ \(0\)\
\-\ outcome\\:\\ 0\\.0036132764569845543\ \(0\)\
\-\ morphology\\:\\ 0\\.0036132764569845543\ \(0\)\
\-\ consult\\:\\ 0\\.0035962102023251626\ \(0\)\
\-\ abdomen\\:\\ 0\\.003585530117416001\ \(0\)\
\-\ primary\\:\\ 0\\.003585530117416001\ \(0\)\
\-\ role\\:\\ 0\\.0035795455441026457\ \(0\)\
\-\ appetite\\:\\ 0\\.003547348395323073\ \(0\)\
\-\ exertion\\:\\ 0\\.003547348395323073\ \(0\)\
\-\ 5\\:\\ 0\\.0035413037145101468\ \(0\)\
\-\ lost\\:\\ 0\\.0035317825973636002\ \(0\)\
\-\ bed\\:\\ 0\\.0035165515738360058\ \(0\)\
\-\ crackles\\:\\ 0\\.0035165515738360058\ \(0\)\
\-\ hemidiaphragm\\:\\ 0\\.0035165515738360058\ \(0\)\
\-\ rates\\:\\ 0\\.0035165515738360058\ \(0\)\
\-\ n\\:\\ 0\\.0035165515738360058\ \(0\)\
\-\ progressed\\:\\ 0\\.0035016412273786175\ \(0\)\
\-\ food\\:\\ 0\\.0035016412273786175\ \(0\)\
\-\ repeated\\:\\ 0\\.0035016412273786175\ \(0\)\
\-\ hemoptysis\\:\\ 0\\.003487038332759116\ \(0\)\
\-\ males\\:\\ 0\\.003487038332759116\ \(0\)\
\-\ respectively\\:\\ 0\\.003487038332759116\ \(0\)\
\-\ throat\\:\\ 0\\.003458705942806071\ \(0\)\
\-\ massive\\:\\ 0\\.003458705942806071\ \(0\)\
\-\ bases\\:\\ 0\\.003458705942806071\ \(0\)\
\-\ classification\\:\\ 0\\.003458705942806071\ \(0\)\
\-\ tend\\:\\ 0\\.0034314635342878024\ \(0\)\
\-\ edema\\:\\ 0\\.0034234043759650014\ \(0\)\
\-\ account\\:\\ 0\\.0034182254797466174\ \(0\)\
\-\ likely\\:\\ 0\\.003414008450333791\ \(0\)\
\-\ lying\\:\\ 0\\.0034052303390467616\ \(0\)\
\-\ childhood\\:\\ 0\\.0034052303390467616\ \(0\)\
\-\ consideration\\:\\ 0\\.003379934246552371\ \(0\)\
\-\ he\\:\\ 0\\.003377035895230906\ \(0\)\
\-\ according\\:\\ 0\\.0033676171483145037\ \(0\)\
\-\ females\\:\\ 0\\.0033676171483145037\ \(0\)\
\-\ cv\\:\\ 0\\.0033555106091082004\ \(0\)\
\-\ rapidly\\:\\ 0\\.0033555106091082004\ \(0\)\
\-\ health\\:\\ 0\\.0033555106091082004\ \(0\)\
\-\ gen\\:\\ 0\\.0033319012463124556\ \(0\)\
\-\ s2\\:\\ 0\\.0033319012463124556\ \(0\)\
\-\ high\\:\\ 0\\.003312388188494073\ \(0\)\
\-\ 2002\\:\\ 0\\.0033090536101805707\ \(0\)\
\-\ genetic\\:\\ 0\\.0033090536101805707\ \(0\)\
\-\ months\\:\\ 0\\.003305865856501512\ \(0\)\
\-\ centrally\\:\\ 0\\.0032979003828660244\ \(0\)\
\-\ gastrointestinal\\:\\ 0\\.0032979003828660244\ \(0\)\
\-\ sites\\:\\ 0\\.0032979003828660244\ \(0\)\
\-\ information\\:\\ 0\\.0032979003828660244\ \(0\)\
\-\ slowly\\:\\ 0\\.0032869200807867285\ \(0\)\
\-\ at\\:\\ 0\\.0032797823026391873\ \(0\)\
\-\ touch\\:\\ 0\\.003265457368679556\ \(0\)\
\-\ incomplete\\:\\ 0\\.003265457368679556\ \(0\)\
\-\ 2005\\:\\ 0\\.003265457368679556\ \(0\)\
\-\ murmurs\\:\\ 0\\.0032549650982934782\ \(0\)\
\-\ therapy\\:\\ 0\\.003236035122153843\ \(0\)\
\-\ fatigue\\:\\ 0\\.0032344356812444327\ \(0\)\
\-\ differentiation\\:\\ 0\\.003224389905754379\ \(0\)\
\-\ abd\\:\\ 0\\.003204715993497243\ \(0\)\
\-\ mild\\:\\ 0\\.0031873278384293726\ \(0\)\
\-\ occasionally\\:\\ 0\\.003185573874242343\ \(0\)\
\-\ grossly\\:\\ 0\\.0031761934020397785\ \(0\)\
\-\ useful\\:\\ 0\\.003157797165210274\ \(0\)\
\-\ 29\\:\\ 0\\.003157797165210274\ \(0\)\
\-\ portions\\:\\ 0\\.003148775192280083\ \(0\)\
\-\ diarrhea\\:\\ 0\\.003139866706297887\ \(0\)\
\-\ fatty\\:\\ 0\\.003139866706297887\ \(0\)\
\-\ that\\:\\ 0\\.003135936392122146\ \(0\)\
\-\ hands\\:\\ 0\\.003131068887602025\ \(0\)\
\-\ pulses\\:\\ 0\\.003131068887602025\ \(0\)\
\-\ each\\:\\ 0\\.003131068887602025\ \(0\)\
\-\ s1\\:\\ 0\\.003122379020327369\ \(0\)\
\-\ neuro\\:\\ 0\\.003122379020327369\ \(0\)\
\-\ \\+\\:\\ 0\\.003122379020327369\ \(0\)\
\-\ particularly\\:\\ 0\\.003122379020327369\ \(0\)\
\-\ nonspecific\\:\\ 0\\.0031137944873724506\ \(0\)\
\-\ 44\\:\\ 0\\.0031053127656679776\ \(0\)\
\-\ significantly\\:\\ 0\\.003096931421725341\ \(0\)\
\-\ feet\\:\\ 0\\.003096931421725341\ \(0\)\
\-\ cns\\:\\ 0\\.003096931421725341\ \(0\)\
\-\ rrr\\:\\ 0\\.0030886481074454603\ \(0\)\
\-\ effusions\\:\\ 0\\.0030886481074454603\ \(0\)\
\-\ over\\:\\ 0\\.003081646728243573\ \(0\)\
\-\ needle\\:\\ 0\\.0030804605561699115\ \(0\)\
\-\ sometimes\\:\\ 0\\.0030804605561699115\ \(0\)\
\-\ enlarging\\:\\ 0\\.0030804605561699115\ \(0\)\
\-\ analysis\\:\\ 0\\.0030804605561699115\ \(0\)\
\-\ 100\\:\\ 0\\.0030564509586658876\ \(0\)\
\-\ date\\:\\ 0\\.003040885160706415\ \(0\)\
\-\ painless\\:\\ 0\\.003040885160706415\ \(0\)\
\-\ 37\\:\\ 0\\.003040885160706415\ \(0\)\
\-\ consolidation\\:\\ 0\\.0030332287045419563\ \(0\)\
\-\ response\\:\\ 0\\.0030332287045419563\ \(0\)\
\-\ chills\\:\\ 0\\.0030256541371788204\ \(0\)\
\-\ by\\:\\ 0\\.0030230968199253714\ \(0\)\
\-\ alert\\:\\ 0\\.0030181597254716414\ \(0\)\
\-\ symptoms\\:\\ 0\\.003016512006937874\ \(0\)\
\-\ pmh\\:\\ 0\\.003010743790721432\ \(0\)\
\-\ overall\\:\\ 0\\.003010743790721432\ \(0\)\
\-\ hx\\:\\ 0\\.002996140896101931\ \(0\)\
\-\ 3rd\\:\\ 0\\.002996140896101931\ \(0\)\
\-\ normally\\:\\ 0\\.0029818330297297496\ \(0\)\
\-\ majority\\:\\ 0\\.0029747860532048434\ \(0\)\
\-\ oriented\\:\\ 0\\.002967808506148886\ \(0\)\
\-\ firm\\:\\ 0\\.002967808506148886\ \(0\)\
\-\ higher\\:\\ 0\\.002967808506148886\ \(0\)\
\-\ 17\\:\\ 0\\.002947279089099841\ \(0\)\
\-\ association\\:\\ 0\\.0029405660976306175\ \(0\)\
\-\ 6\\.\\:\\ 0\\.0029405660976306175\ \(0\)\
\-\ surgery\\:\\ 0\\.002939092159150531\ \(0\)\
\-\ heent\\:\\ 0\\.0029273280430894325\ \(0\)\
\-\ almost\\:\\ 0\\.0029273280430894325\ \(0\)\
\-\ testing\\:\\ 0\\.0029273280430894325\ \(0\)\
\-\ unusual\\:\\ 0\\.0029273280430894325\ \(0\)\
\-\ gallbladder\\:\\ 0\\.0029079236704349608\ \(0\)\
\-\ numbness\\:\\ 0\\.0029079236704349608\ \(0\)\
\-\ become\\:\\ 0\\.0028828514841382777\ \(0\)\
\-\ fevers\\:\\ 0\\.002876719711657319\ \(0\)\
\-\ rather\\:\\ 0\\.002876719711657319\ \(0\)\
\-\ hematuria\\:\\ 0\\.0028706405730656815\ \(0\)\
\-\ reflexes\\:\\ 0\\.002864613172451015\ \(0\)\
\-\ dyspnea\\:\\ 0\\.002864613172451015\ \(0\)\
\-\ dense\\:\\ 0\\.0028586366365828393\ \(0\)\
\-\ form\\:\\ 0\\.0028294878600293636\ \(0\)\
\-\ despite\\:\\ 0\\.0028125576044673566\ \(0\)\
\-\ t\\:\\ 0\\.0028014915153008685\ \(0\)\
\-\ unable\\:\\ 0\\.002796022644129544\ \(0\)\
\-\ reflux\\:\\ 0\\.002796022644129544\ \(0\)\
\-\ other\\:\\ 0\\.002789856301278256\ \(0\)\
\-\ showing\\:\\ 0\\.0027852099868131215\ \(0\)\
\-\ term\\:\\ 0\\.0027692943665212954\ \(0\)\
\-\ 11\\:\\ 0\\.0027692943665212954\ \(0\)\
\-\ l\\:\\ 0\\.0027588792479733525\ \(0\)\
\-\ r\\:\\ 0\\.002748615078495614\ \(0\)\
\-\ present\\:\\ 0\\.0027337234474952986\ \(0\)\
\-\ few\\:\\ 0\\.00272358719857684\ \(0\)\
\-\ distribution\\:\\ 0\\.00272358719857684\ \(0\)\
\-\ poor\\:\\ 0\\.00272358719857684\ \(0\)\
\-\ it\\:\\ 0\\.0027207484200184374\ \(0\)\
\-\ factors\\:\\ 0\\.0027186860350891812\ \(0\)\
\-\ from\\:\\ 0\\.0026907274358800547\ \(0\)\
\-\ circumscribed\\:\\ 0\\.0026899706707872333\ \(0\)\
\-\ admission\\:\\ 0\\.002666899728553089\ \(0\)\
\-\ represent\\:\\ 0\\.002657877755622898\ \(0\)\
\-\ case\\:\\ 0\\.002648023276015964\ \(0\)\
\-\ recurrence\\:\\ 0\\.0026401714509448402\ \(0\)\
\-\ development\\:\\ 0\\.002635813189206612\ \(0\)\
\-\ young\\:\\ 0\\.002635813189206612\ \(0\)\
\-\ growth\\:\\ 0\\.002631481583670184\ \(0\)\
\-\ do\\:\\ 0\\.0026271763102449844\ \(0\)\
\-\ frequently\\:\\ 0\\.0026228970507152657\ \(0\)\
\-\ review\\:\\ 0\\.0026228970507152657\ \(0\)\
\-\ admitted\\:\\ 0\\.0026144153290107927\ \(0\)\
\-\ children\\:\\ 0\\.0026144153290107927\ \(0\)\
\-\ 5\\.\\:\\ 0\\.002610212258529338\ \(0\)\
\-\ another\\:\\ 0\\.0026018802177505936\ \(0\)\
\-\ intermittent\\:\\ 0\\.002597750670788276\ \(0\)\
\-\ metastases\\:\\ 0\\.0025855045680191107\ \(0\)\
\-\ al\\:\\ 0\\.0025655535220087027\ \(0\)\
\-\ before\\:\\ 0\\.0025616298815160574\ \(0\)\
\-\ and\\/or\\:\\ 0\\.0025577278589870417\ \(0\)\
\-\ site\\:\\ 0\\.0025577278589870417\ \(0\)\
\-\ ed\\:\\ 0\\.0025577278589870417\ \(0\)\
\-\ features\\:\\ 0\\.002553847217510678\ \(0\)\
\-\ oral\\:\\ 0\\.00254998772404923\ \(0\)\
\-\ best\\:\\ 0\\.0025461491493542305\ \(0\)\
\-\ s\\/p\\:\\ 0\\.0025385338577279828\ \(0\)\
\-\ outside\\:\\ 0\\.0025385338577279828\ \(0\)\
\-\ involved\\:\\ 0\\.0025385338577279828\ \(0\)\
\-\ mid\\:\\ 0\\.002530999581378793\ \(0\)\
\-\ references\\:\\ 0\\.0025161673052844285\ \(0\)\
\-\ an\\:\\ 0\\.0025106194000383782\ \(0\)\
\-\ recommended\\:\\ 0\\.0025088660519849517\ \(0\)\
\-\ i\\:\\ 0\\.0025016393025697665\ \(0\)\
\-\ related\\:\\ 0\\.0024980533946685293\ \(0\)\
\-\ especially\\:\\ 0\\.002490935593072565\ \(0\)\
\-\ pelvic\\:\\ 0\\.002483888616547658\ \(0\)\
\-\ tissues\\:\\ 0\\.002483888616547658\ \(0\)\
\-\ occurs\\:\\ 0\\.002483888616547658\ \(0\)\
\-\ family\\:\\ 0\\.002480391249946679\ \(0\)\
\-\ pathology\\:\\ 0\\.002476911069491701\ \(0\)\
\-\ et\\:\\ 0\\.002476911069491701\ \(0\)\
\-\ tender\\:\\ 0\\.0024563816524426556\ \(0\)\
\-\ slightly\\:\\ 0\\.0024463358769526013\ \(0\)\
\-\ includes\\:\\ 0\\.0024397169942201387\ \(0\)\
\-\ cells\\:\\ 0\\.0024266619646954655\ \(0\)\
\-\ currently\\:\\ 0\\.002398139373238001\ \(0\)\
\-\ use\\:\\ 0\\.002391954047481093\ \(0\)\
\-\ pleural\\:\\ 0\\.0023501063729980854\ \(0\)\
\-\ malignancy\\:\\ 0\\.0023385904233721787\ \(0\)\
\-\ 30\\:\\ 0\\.0023272587368662005\ \(0\)\
\-\ skin\\:\\ 0\\.0023244539201409194\ \(0\)\
\-\ cough\\:\\ 0\\.002318877392923564\ \(0\)\
\-\ course\\:\\ 0\\.002283662495365185\ \(0\)\
\-\ referred\\:\\ 0\\.002283662495365185\ \(0\)\
\-\ hospital\\:\\ 0\\.00227839692986411\ \(0\)\
\-\ occur\\:\\ 0\\.0022705712668424495\ \(0\)\
\-\ 8\\:\\ 0\\.0022628311319046377\ \(0\)\
\-\ ago\\:\\ 0\\.002252640807930063\ \(0\)\
\-\ weakness\\:\\ 0\\.002247600108377043\ \(0\)\
\-\ diagnosed\\:\\ 0\\.0022253506776168594\ \(0\)\
\-\ year\\-old\\:\\ 0\\.002222921120182873\ \(0\)\
\-\ since\\:\\ 0\\.002222921120182873\ \(0\)\
\-\ above\\:\\ 0\\.0022180868673001533\ \(0\)\
\-\ involvement\\:\\ 0\\.0022180868673001533\ \(0\)\
\-\ early\\:\\ 0\\.0022132853892651828\ \(0\)\
\-\ ap\\:\\ 0\\.0022132853892651828\ \(0\)\
\-\ reported\\:\\ 0\\.0022061436618808867\ \(0\)\
\-\ pelvis\\:\\ 0\\.002199073234130049\ \(0\)\
\-\ presence\\:\\ 0\\.0021967320244030662\ \(0\)\
\-\ peripheral\\:\\ 0\\.002189754477347109\ \(0\)\
\-\ male\\:\\ 0\\.0021886763992740414\ \(0\)\
\-\ 20\\:\\ 0\\.0021760022918959035\ \(0\)\
\-\ then\\:\\ 0\\.0021536592623385906\ \(0\)\
\-\ palpable\\:\\ 0\\.0021449157525494267\ \(0\)\
\-\ effect\\:\\ 0\\.0021427466381510234\ \(0\)\
\-\ \\.\\:\\ 0\\.002137011733905406\ \(0\)\
\-\ location\\:\\ 0\\.0021109827810934087\ \(0\)\
\-\ sign\\:\\ 0\\.0020966334998329117\ \(0\)\
\-\ benign\\:\\ 0\\.0020885625828847036\ \(0\)\
\-\ liver\\:\\ 0\\.002086559143649238\ \(0\)\
\-\ headache\\:\\ 0\\.0020786015846783273\ \(0\)\
\-\ elevated\\:\\ 0\\.0020533401992627923\ \(0\)\
\-\ cause\\:\\ 0\\.0020476364210707974\ \(0\)\
\-\ 10\\:\\ 0\\.002040102144721608\ \(0\)\
\-\ possible\\:\\ 0\\.002038231033204017\ \(0\)\
\-\ areas\\:\\ 0\\.002036364852157271\ \(0\)\
\-\ recent\\:\\ 0\\.0020345035756655786\ \(0\)\
\-\ followed\\:\\ 0\\.002028948917407062\ \(0\)\
\-\ x\\:\\ 0\\.001996505903220593\ \(0\)\
\-\ study\\:\\ 0\\.0019912403377195177\ \(0\)\
\-\ often\\:\\ 0\\.0019309302751555613\ \(0\)\
\-\ mr\\:\\ 0\\.0019229458016617807\ \(0\)\
\-\ known\\:\\ 0\\.0019150503431046883\ \(0\)\
\-\ area\\:\\ 0\\.001913481759301889\ \(0\)\
\-\ any\\:\\ 0\\.0019056905333373186\ \(0\)\
\-\ enhancing\\:\\ 0\\.001897984088445297\ \(0\)\
\-\ resection\\:\\ 0\\.001887334033654546\ \(0\)\
\-\ days\\:\\ 0\\.0018548684817081996\ \(0\)\
\-\ age\\:\\ 0\\.0018420044798472426\ \(0\)\
\-\ diffuse\\:\\ 0\\.00183215822972756\ \(0\)\
\-\ only\\:\\ 0\\.0018196966419864985\ \(0\)\
\-\ neck\\:\\ 0\\.001777084374658982\ \(0\)\
\-\ years\\:\\ 0\\.001777084374658982\ \(0\)\
\-\ loss\\:\\ 0\\.001756702671719858\ \(0\)\
\-\ lung\\:\\ 0\\.0017529455525770157\ \(0\)\
\-\ fluid\\:\\ 0\\.0017199993658667517\ \(0\)\
\-\ all\\:\\ 0\\.0017117021879825007\ \(0\)\
\-\ time\\:\\ 0\\.0017093493110760004\ \(0\)\
\-\ however\\:\\ 0\\.0016851048552387186\ \(0\)\
\-\ presented\\:\\ 0\\.001649686710355814\ \(0\)\
\-\ been\\:\\ 0\\.0016464553041529682\ \(0\)\
\-\ significant\\:\\ 0\\.0016273705035794784\ \(0\)\
\-\ lesions\\:\\ 0\\.0016200853444362237\ \(0\)\
\-\ these\\:\\ 0\\.0015749608299984704\ \(0\)\
\-\ patients\\:\\ 0\\.0015662709627238143\ \(0\)\
\-\ anterior\\:\\ 0\\.0015586351443078877\ \(0\)\
\-\ prior\\:\\ 0\\.0015539042296050733\ \(0\)\
\-\ both\\:\\ 0\\.001545467415500086\ \(0\)\
\-\ on\\:\\ 0\\.0015380120659322129\ \(0\)\
\-\ none\\:\\ 0\\.001501217781096322\ \(0\)\
\-\ \\`\\`\\:\\ 0\\.0014873477603624767\ \(0\)\
\-\ bilateral\\:\\ 0\\.0014687094400243938\ \(0\)\
\-\ \\'\\'\\:\\ 0\\.001458746106219719\ \(0\)\
\-\ chest\\:\\ 0\\.0014481083569812456\ \(0\)\
\-\ into\\:\\ 0\\.0014400328384983761\ \(0\)\
\-\ noted\\:\\ 0\\.001434434269442347\ \(0\)\
\-\ without\\:\\ 0\\.0014249385030865157\ \(0\)\
\-\ imaging\\:\\ 0\\.0014178993091045345\ \(0\)\
\-\ was\\:\\ 0\\.0013998265187162703\ \(0\)\
\-\ this\\:\\ 0\\.0013613841548358826\ \(0\)\
\-\ lower\\:\\ 0\\.0013610921171132173\ \(0\)\
\-\ \\'s\\:\\ 0\\.001334310636237284\ \(0\)\
\-\ demonstrates\\:\\ 0\\.0013219696895560807\ \(0\)\
\-\ surgical\\:\\ 0\\.0012721117353055621\ \(0\)\
\-\ after\\:\\ 0\\.0012521254975985854\ \(0\)\
\-\ treatment\\:\\ 0\\.001224941189519042\ \(0\)\
\-\ patient\\:\\ 0\\.0012133030182951672\ \(0\)\
\-\ also\\:\\ 0\\.0011930733666219203\ \(0\)\
\-\ normal\\:\\ 0\\.0009487340330021963\ \(0\)\
\-\ not\\:\\ 0\\.0008745174729050534\ \(0\)\
\-\ ct\\:\\ 0\\.0008465323324306253\ \(0\)\
\-\ with\\:\\ 0\\.0007457773263519884\ \(0\)\
\-\ right\\:\\ 0\\.0006385493690583688\ \(0\)\
